Jacobs Solutions Inc. was selected by FUJIFILM Diosynth Biotechnologies to support delivery of $1.2 billion expansion of an end-to-end, large-scale cell culture contract manufacturing site in Holly Springs, North Carolina. Jacobs was originally selected to support the construction for the FUJIFILM Diosynth Biotechnologies' Holly Springs site, which broke ground in 2021. Jacobs will provide engineering, procurement and construction management services for the site's latest expansion.

The expansion will leverage the existing engineering and facility designs, with an additional 8 x 20,000 liter (L) cell culture bioreactors and approximately 400,000 square feet of manufacturing space by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment. The first phase of construction is planned for completion in 2025.